• Lemonilo Launches "Healthy Café & Ropang Movement" in Jakarta

    Culinary is certainly a promising business in Indonesia, particularly in Jakarta. Jakarta Dining Index Research done by Qraved reveals that every year, Jakartans dine out as many as 380 million times and spend up to IDR 21.4 trillion (approx. USD $1.5 billion). This fact is supported by huge growth of mid-scale restaurants (amounting up to 250 percent) in the last five years. It is therefore not surprising that Jakarta has an abundant option of restaurants.

    Read column ›

  • Explaining the Volatile Performance of Perusahaan Gas Negara's Shares

    Shares of Perusahaan Gas Negara, Indonesia's largest natural gas transportation and distribution company, have been performing in a very volatile manner so far in 2018. While in late February 2018 the company's shares had surged 55.43 percent to IDR 2,720 per share since the year-start, some five months later the same shares plunged to IDR 1,525 a piece (down 12.86 percent since the start of the year). What is going on with Perusahaan Gas Negara that can explain this volatile stock performance?

    Read column ›

  • CEOs' Optimism about Indonesian Economy & Politics Falls Slightly

    Chief executive officers (CEOs) in Indonesia have become slightly less optimistic about the Indonesian economy and politics. This makes sense considering the presence of simmering global trade tensions, sharp rupiah depreciation against the US dollar, and Bank Indonesia's recent series of interest rate hikes.

    Read column ›

  • How Big Indonesian Pharmaceutical Firms Cope with Rupiah Weakness

    One of the national industries that is heavily affected by the weak rupiah exchange rate is Indonesia's pharmaceutical industry. Considering around 90 percent of raw materials in the pharmaceutical industry need to be imported from abroad (in US dollars), production costs rise sharply in times of significant rupiah depreciation. It is estimated that materials imported from abroad account for about 75 percent of pharmaceutical companies' total production costs.

    Read column ›


The views expressed in these business columns are the views of the authors or the interviewed persons only and therefore do not necessarily reflect the views of Indonesia Investments. The authors are free to ventilate their opinions about the Indonesian business climate. Facts presented in these columns are the result of the author's own research or indicated sources, read disclaimer
.